Frankenfield Christopher James

SEC source: 0001193125-26-002517 · ownership.xml · nonDerivative · entry 2

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,766

F2 · kind: The reported sale of 7,030 shares occurred automatically in a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units.

SEC source: 0001193125-26-002517 · ownership.xml · derivative · entry 4

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,750

Underlying: Common Stock · 19,375 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert to stock on a one-for-one basis.

F6 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025.

F6 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025.

SEC source: 0001193125-26-002517 · ownership.xml · nonDerivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,796

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert to stock on a one-for-one basis.

SEC source: 0001193125-26-002517 · ownership.xml · derivative · entry 3

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 668,789

Underlying: Common Stock · 668,789 shares

Expires 2035-10-07

F3 · date: On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 3 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met.

F4 · shares: The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025.

F5 · derivative.exercise_date: This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 17

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2033-08-15

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 16

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 300,000 shares

Expires 2033-08-15

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 15

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-08-02

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F8 · derivative.exercise_date: This option was granted on August 3, 2023. The shares underlying the option began vesting on September 1, 2023 and continue to vest in equal monthly installments thereafter through August 1, 2027.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 14

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires 2033-08-02

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F8 · derivative.exercise_date: This option was granted on August 3, 2023. The shares underlying the option began vesting on September 1, 2023 and continue to vest in equal monthly installments thereafter through August 1, 2027.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 13

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,000

Underlying: Common Stock · 117,000 shares

Expires 2032-12-31

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F7 · derivative.exercise_date: This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 12

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 117,000 shares

Expires 2032-12-31

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F7 · derivative.exercise_date: This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 11

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-08-31

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F6 · derivative.exercise_date: This option was granted on September 1, 2022. The shares underlying the option began vesting on September 1, 2022 and continue to vest in equal monthly installments thereafter through August 1, 2026.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 10

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2032-08-31

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F6 · derivative.exercise_date: This option was granted on September 1, 2022. The shares underlying the option began vesting on September 1, 2022 and continue to vest in equal monthly installments thereafter through August 1, 2026.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 9

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2032-02-21

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F5 · derivative.exercise_date: This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 8

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,000 shares

Expires 2032-02-21

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F5 · derivative.exercise_date: This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 7

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,296

Underlying: Common Stock · 37,296 shares

Expires 2031-10-20

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 6

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,296 shares

Expires 2031-10-20

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 5

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,786

Underlying: Common Stock · 23,786 shares

Expires 2031-03-31

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 4

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,786 shares

Expires 2031-03-31

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 3

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,090

Underlying: Common Stock · 155,090 shares

Expires 2031-03-28

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 2

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 155,090 shares

Expires 2031-03-28

F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001193125-25-297204 · ownership.xml · derivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 925,000

Underlying: Common Stock · 925,000 shares

Expires 2035-10-07

F1 · date: On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 1 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025.

F2 · derivative.exercise_date: The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.

SEC source: 0001415889-25-010804 · form4-04162025_040404.xml · derivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-04-14

F1 · derivative.exercise_date: The option was granted on April 15, 2025 and will vest in equal monthly installments beginning on May 1, 2025 through April 1, 2029.

SEC source: 0001415889-25-000407 · form4-01032025_040116.xml · nonDerivative · entry 2

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,421

F2 · kind: The reported sale of 6,954 shares occurred automatically in a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units.

SEC source: 0001415889-25-000407 · form4-01032025_040116.xml · derivative · entry 4

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 251,000

Underlying: Common Stock · 251,000 shares

Expires 2035-12-31

F4 · derivative.exercise_date: The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029.

SEC source: 0001415889-25-000407 · form4-01032025_040116.xml · derivative · entry 3

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,125

Underlying: Common Stock · 19,375 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis

F3 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.

F3 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.

SEC source: 0001415889-25-000407 · form4-01032025_040116.xml · nonDerivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis

SEC source: 0001415889-24-020847 · form4-08062024_080802.xml · derivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common Stock · 52,000 shares

Expires 2034-08-02

F1 · derivative.exercise_date: The option was granted on August 3, 2024 and will vest in equal monthly installments beginning on September 1, 2024 through August 1, 2028.

SEC source: 0001415889-24-012150 · form4-05032024_040504.xml · derivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,000

Underlying: Common Stock · 208,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028.

SEC source: 0001415889-24-000305 · form4-01032024_090105.xml · derivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Common Stock · 77,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.

F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.

SEC source: 0001415889-23-012417 · form4-08182023_080801.xml · derivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2033-08-15

F1 · derivative.exercise_date: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.

SEC source: 0001104659-23-088350 · tm2323038-2_4seq1.xml · derivative · entry 1

Frankenfield Christopher James · CIK 0001988344 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-08-02

F1 · derivative.exercise_date: The option was granted on August 3, 2023 and will vest in equal monthly installments beginning on September 1, 2023 through August 1, 2027.